Cargando…

Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis

BACKGROUND: Adalimumab has been used in patients with moderately to severely active rheumatoid arthritis (RA) for over 10 years and has a well-established safety profile across multiple indications. OBJECTIVE: To update adverse events (AEs) of special interest from global adalimumab clinical trials...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burmester, Gerd R, Landewé, Robert, Genovese, Mark C, Friedman, Alan W, Pfeifer, Nathan D, Varothai, Nupun A, Lacerda, Ana P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5284339/ https://www.ncbi.nlm.nih.gov/pubmed/27338778 http://dx.doi.org/10.1136/annrheumdis-2016-209322

Ejemplares similares

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
por: Burmester, Gerd R, et al.
Publicado: (2013)

Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial
por: Burmester, Gerd-Rűdiger, et al.
Publicado: (2015)

Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial
por: Burmester, Gerd R, et al.
Publicado: (2017)

Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension
por: Burmester, Gerd R, et al.
Publicado: (2019)

Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study
por: Cohen, Stanley, et al.
Publicado: (2017)

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2013)

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
por: Mease, P J, et al.
Publicado: (2008)

Long-term treatment of rheumatoid arthritis with adalimumab
por: Murdaca, Giuseppe, et al.
Publicado: (2013)

Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
por: Neovius, M, et al.
Publicado: (2015)

Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate
por: Smolen, Josef S, et al.
Publicado: (2013)

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
por: Smolen, J, et al.
Publicado: (2008)

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
por: Schiff, Michael, et al.
Publicado: (2014)

Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study
por: Burmester, Gerd R, et al.
Publicado: (2014)

Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
por: Genovese, Mark C., et al.
Publicado: (2016)

Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)
por: Burmester, Gerd R, et al.
Publicado: (2010)

Carbamylation of vimentin is inducible by smoking and represents an independent autoantigen in rheumatoid arthritis
por: Ospelt, Caroline, et al.
Publicado: (2017)

Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab
por: Listing, Joachim, et al.
Publicado: (2015)

Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years’ follow-up
por: Fleischmann, Roy, et al.
Publicado: (2020)

Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss
por: Wijbrandts, C A, et al.
Publicado: (2008)

Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study
por: Hoff, M, et al.
Publicado: (2008)

Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study
por: Tanaka, Yoshiya, et al.
Publicado: (2015)

Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab
por: Burmester, Gerd R, et al.
Publicado: (2017)

Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
por: Conaghan, Philip, et al.
Publicado: (2021)

Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2023)

Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial
por: Burmester, Gerd R, et al.
Publicado: (2016)

Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension
por: Keystone, Edward, et al.
Publicado: (2014)

Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases
por: Burmester, G R, et al.
Publicado: (2009)

Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study
por: Emery, Paul, et al.
Publicado: (2020)

Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis
por: Gabay, Cem, et al.
Publicado: (2016)

Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis
por: Alten, Rieke, et al.
Publicado: (2020)

Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group
por: Halpern, M T, et al.
Publicado: (2008)

Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2017)

Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
por: Gissel, C., et al.
Publicado: (2016)

Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis
por: Lu, XiaoQin, et al.
Publicado: (2021)

Smoking and overweight determine the likelihood of developing rheumatoid arthritis
por: de Hair, Maria J H, et al.
Publicado: (2013)

Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong
por: Li, Xue, et al.
Publicado: (2022)

Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research
por: Salliot, C, et al.
Publicado: (2008)

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
por: Combe, Bernard, et al.
Publicado: (2021)

Association of High Serum Interleukin‐6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis
por: Boyapati, Anita, et al.
Publicado: (2020)

The US7 score is sensitive to change in a large cohort of patients with rheumatoid arthritis over 12 months of therapy
por: Backhaus, Tina M, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_b420scnv717l70ov9cmqtqt24h